Change in heparin potency and effects on the activated clotting time in children undergoing cardiopulmonary bypass

Anesthesia and Analgesia

Volumn 115, Issue 4, 2012, Pages 921-924

  Guzzetta, Nina A ^a   Amin, Sapan J ^a,b   Tosone, Alexandra K ^a,c   Miller, Bruce E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^c AGNES SCOTT COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

AGE DISTRIBUTION; ANTICOAGULATION; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CHILD; CHILD HEALTH CARE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RELEASE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEWBORN; PEDIATRIC SURGERY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW;

BLOOD COAGULATION; CARDIOPULMONARY BYPASS; FEMALE; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WHOLE BLOOD COAGULATION TIME;

EID: 84866937763     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e318267056b     Document Type: Review

References (13)

1. Smythe MA, Nutescu EA, Wittkowsky AK. Changes in the USP heparin monograph and implications for clinicians. Pharmacotherapy 2010;30:428-31
2. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67
3. Honchel R, Carraway J, Gopee N, Callicott R, Chen J, Patton R, Xu Q, Zalkkar J, Laniyonu A, Krefting I, Cato M, Robie-Suh K, Rieves R. A dose-response study in animals to evaluate the anticoagulant effect of the stage 2 unfractionated heparin USP monograph change. Regul Toxicol Pharm 2011;60:318-22
4. Voelker R. New standards reduce heparin potency. JAMA 2009;302:1956
5. Hirsh J. Mechanism of action and monitoring of anticoagulants. Semin Thromb Hemostas 1986;12:1-11
6. Culliford AT, Gitel SN, Starr N, Thomas ST, Baumann FG, Wessler S, Spencer FC. Lack of correlation between activated clotting time and plasma heparin levels during cardiopulmonary bypass. Ann Surg 1981;193:105-11
7. Guzzetta NA, Monitz HG, Fernandez JD, Fazlollah TM, Knezevic A, Miller BE. Correlations between ACT values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Anesth Analg 2010;111:173-9
8. Andrew M, MacIntyre B, MacMillan J, Williams WG, Gruenwald C, Johnston M, Burrows F, Wang E, Adams M. Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Thromb Haemostas 1993;70:937-41
9. Andrew M. Anticoagulation and thrombolysis in children. Texas Heart Institute J 1992;19:168-77
10. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated clotting time of heparinized blood. Anesth Analg 1984;63:394-8
11. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991;87:1787-93
12. Saba HI, Saba SR, Morelli GA. Effect of heparin on platelet aggregation. Am J Hematol 1984;17:295-306
13. Khuri SF, Valeri CR, Loscalzo J, Weinstein MJ, Birjiniuk V, Healey NA, MacGregor H, Doursounian M, Zolkewitz. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 1995;60:1008-14